Skip to main content

Advertisement

Log in

Soluble levels of Osteopontin in Patients with Behcet's Disease: Association with Disease Activity and Vascular Involvement

  • Original Research
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Aim

Osteopontin (OPN) is a multifunctional molecule highly expressed in chronic inflammatory and autoimmune diseases. We aimed to assess the plasma OPN levels in Behcet's disease (BD) patients and identify potential associations between these levels with disease activity, severity and clinical manifestations with special emphasis on vascular affection.

Methods

We studied 55 BD patients and 31 age- and gender-matched healthy controls. Demographic, clinical and serological data were prospectively assessed. Activity and severity of BD were assessed using clinical scores and laboratory parameters. Plasma OPN levels were measured using enzyme-linked immunosorbent assay (ELISA).

Results

Plasma OPN levels were significantly higher in patients with BD compared to healthy controls (p < 0.000). The means for plasma OPN levels in active and inactive BD patients were significantly higher than that for the normal controls (with p < 0.000 and p = 0.002 respectively). The mean OPN levels significantly associated with the BD clinical severity score from mild to severe (p = 0.011). BD patients with vascular involvement had significant elevation of plasma OPN levels than those without (P = 0.03). OPN levels positively correlated with severity score, IL6, hsCRP, ESR, leucocytes count and neutrophil count.

Conclusion

Plasma OPN levels were higher in BD patients than in healthy controls and were found to be associated with disease activity, severity and vascular involvement. To confirm our results we propose that larger scale, multicentre studies with longer evaluation periods are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yazici Y, Yurdakul S, Yazici H. Behcet's syndrome. Curr Rheumatol Rep. 2010;12(6):429–35.

    Article  PubMed  Google Scholar 

  2. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's Disease. Autoimmun Rev. 2011 Dec 16. [Epub ahead of print].

  3. Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec Family of Tyrosine Kinases, in patients with Behcet’s Disease. Clin Med Res. 2006;4(2):147–51.

    Article  PubMed  CAS  Google Scholar 

  4. Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB. Imbalance of Th17 to Th1 cells in Behcet's disease. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S16–9.

    PubMed  Google Scholar 

  5. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008;19(5–6):333–45.

    Article  PubMed  CAS  Google Scholar 

  6. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–9.

    Article  PubMed  CAS  Google Scholar 

  7. Cho HJ, Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009;11(3):206–13.

    Article  PubMed  CAS  Google Scholar 

  8. Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, Bi S. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2012;244(1–2):94–6.

    Article  PubMed  CAS  Google Scholar 

  9. Gao SG, Li KH, Zeng KB, Tu M, Xu M, Lei GH. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage. 2010;18(1):82–7.

    Article  PubMed  CAS  Google Scholar 

  10. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44:2097–106.

    Article  PubMed  CAS  Google Scholar 

  11. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002;29:2061–7.

    PubMed  CAS  Google Scholar 

  12. Mishima R, Takeshima F, Sawai T, Ohba K, Ohnita K, Isomoto H, Omagari K, Mizuta Y, Ozono Y, Kohno S. High plasma osteopontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol. 2007;41(2):167–72.

    Article  PubMed  CAS  Google Scholar 

  13. Lorenzen JM, Krämer R, Meier M, Werfel T, Wichmann K, Hoeper MM, Riemekasten G, Becker MO, Haller H, Witte T. Osteopontin in the development of systemic sclerosis–relation to disease activity and organ manifestation. Rheumatology (Oxford). 2010;49(10):1989–91.

    Article  CAS  Google Scholar 

  14. Lorenzen J, Lovric S, Krämer R, Haller H, Haubitz M. Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. Ann Rheum Dis. 2010;69(6):1169–71.

    Article  PubMed  CAS  Google Scholar 

  15. Erturkler E, Cıcek D, Kaman D, Ozdogan S, Bakar Dertlıoglu S. Plasma osteopontin levels in patients with Behcet's disease and psoriasis. Eur J Dermatol. 2011;21(2):203–8.

    PubMed  Google Scholar 

  16. Chu M, Yang P, Hou S, Li F, Chen Y, Kijlstra A. Behcet’s disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms. Hum Immunol. 2011;729(6):525–9.

    Article  Google Scholar 

  17. International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335:1078–80.

    Google Scholar 

  18. Choe JY, Park SH, Kim SK. Serum angiopoietin-1 level is increased in patients with Behçet's disease. Joint Bone Spine. 2010;77(4):340–4.

    Article  PubMed  CAS  Google Scholar 

  19. Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, Direskeneli H. Oral health is impaired in Behçet's disease and is associated with disease severity. Rheumatology. 2004;43:1028–33.

    Article  PubMed  CAS  Google Scholar 

  20. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–4.

    Article  PubMed  CAS  Google Scholar 

  21. Koh A, da Silva AP, Bansal AK, Bansal M, Sun C, Lee H, Glogauer M, Sodek J, Zohar R. Role of osteopontin in neutrophil function. Immunology. 2007;122:466–75.

    Article  PubMed  CAS  Google Scholar 

  22. Kitamura M, Iwabuchi K, Kitaichi N, Kon S, Kitamei H, Namba K, Yoshida K, Denhardt DT, Rittling SR, Ohno S, Uede T, Onoé K. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J Immunol. 2007;178:6567–72.

    PubMed  CAS  Google Scholar 

  23. Liaw L, Lombardi DM, Almeida MM, Schwartz SM, deBlois D, Giachelli CM. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol. 1997;17:188–93.

    Article  PubMed  CAS  Google Scholar 

  24. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, Ohsuzu F. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res. 2002;91:77–82.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There are no conflicts of interest related to the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Iman H. Bassyouni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bassyouni, I.H., El-Wakd, M.M. & Bassyouni, R.H. Soluble levels of Osteopontin in Patients with Behcet's Disease: Association with Disease Activity and Vascular Involvement. J Clin Immunol 33, 361–367 (2013). https://doi.org/10.1007/s10875-012-9820-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-012-9820-y

Keywords

Navigation